Immunogen launches phase I trial for NHL drug


Biotech company Immunogen has launched a phase I trial for its IMGN529 anti-cancer drug candidate.

This phase I trial will evaluate the safety, tolerability, pharmacokinetic profile and anticancer activity of escalating doses of IMGN529 in patients with non-Hodgkin's lymphoma (NHL) to establish the dose for future clinical trials.

The trial is multi-center and first-in-human and it is expected to enroll approximately 55 patients with relapsed or relapsed/refractory, CD37-expressing NHL. Patients with follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, or marginal zone lymphoma -- the more common types of NHL -- are eligible for enrollment.

IMGN529 is a so-called TAP compound, or Targeted Antibody Payload compound. It has a CD-37 targeting monoclonal antibody that targets B-cells coupled with Immunogen's cell-killing agent DM1. The TAP technology allows the antibody to deliver the toxic payload directly to the cells in question.

Source: MarketWatch

LymphomaInfo Social